Nicox: signs agreement for Zerviate in the Gulf

(CercleFinance.com) - Nicox today announces an exclusive licence agreement with ITROM Pharmaceutical Group for the registration and marketing of Zerviate, 0.
24% for the treatment of eye pruritus associated with allergic conjunctivities in the Arab State of the Gulf.

It has thus granted ITROM the exclusive rights to develop and market the product in Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Oman, Qatar, Saudi Arabia, United Arab Emirates and Yemen.

Nicox could receive 15% fees on net sales in some key territories and 10% in others. It will also receive a milestone payment on the agreement's signature and could receive a milestone payment on its commercial launch.


Copyright (c) 2020 CercleFinance.com. All rights reserved.